Research
Hormonal
Preliminary reports have raised concerns about a possible association between GLP-1 RA use and erectile dysfunction.
Clinicians should monitor erectile function in patients using GLP-1 RAs.
StrongQualifiesmedium confidence
However, preliminary reports have also raised concerns about a possible association between GLP-1 RA use and ED.
Why this rating
The claim is based on emerging evidence that warrants further investigation.
Source
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Dimitris Kounatidis et al. · Biomolecules · 2025
DOI 10.3390/biom15091284
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →